

ASX Announcement

10 April 2026

Change of Share Registry Details

Oncosil Medical Ltd (ASX: OSL) advises that as of Monday 13 April 2026, Oncosil Medical Ltd has changed its provider for shareholder registry services from Boardroom Pty Limited to Automic Pty Ltd (“Automic”).

The Company’s new Share registry contact details are as follows:

Automic
Level 5, 126 Phillip Street
Sydney NSW 2000

GPO Box 5193
Sydney NSW 2001

Shareholders can easily and efficiently manage their holdings via Automic’s secure and highly accessible online investor portal. The portal provides, among other things, an online interface to update and manage shareholder details, view balances and transaction history.

Shareholder registration online

Shareholders that are not already a user of Automic’s investor portal may visit <https://investor.automic.com.au> and sign up to register their details using the two simple steps provided in the setup process.

Shareholders with any queries in relation to their Oncosil Medical Ltd holding are advised to contact Automic at hello@automicgroup.com.au or on 1300 288 664 (within Australia) or +61 2 9698 5414 (outside Australia).

This announcement has been authorised for release by the Board of Directors of OncoSil Medical Ltd.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	Mr. Tim Luscombe Company Secretary E: tim.luscombe@bio101.com T: +61 429 707 079	Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 7257 7338
--	---	---

About OncoSil Medical

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical’s mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year¹. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel and the UK.

To learn more, please visit: www.oncosil.com/

1. <https://gco.iarc.fr/en>